SynthesisEndocrine2026
GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTobacco use remains the leading preventable cause of morbidity and mortality worldwide, with current cessation therapies yielding suboptimal long-term abstinence. This systematic review evaluates the efficacy, tolerability, and neurobiological rationale of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonists in treating nicotine use disorder (NUD), with particular attention to smoking abstinence, craving reduction, weight gain mitigation, and mechanistic insights.
methodsFollowing PRISMA guidelines, a comprehensive search was conducted across PubMed, Embase, CENTRAL, PsycINFO, and Web of Science through April 2025. Eligible studies included randomized controlled trials (RCTs), observational cohorts, and preclinical rodent studies evaluating GLP-1 or GLP-1/GIP agonists in nicotine-related outcomes. Risk of bias was assessed using Cochrane RoB2, ROBINS-I, and SYRCLE tools. Narrative synthesis was conducted due to heterogeneity in study designs and outcome definitions.
resultsTwelve studies met inclusion criteria—eight human and four preclinical. Preclinical studies demonstrated consistent attenuation of nicotine-seeking behavior and mesolimbic dopaminergic signaling via GLP-1R agonism. Among human studies, exenatide showed the most robust efficacy in enhancing abstinence and reducing craving and weight gain. Dulaglutide did not improve abstinence, though it conferred metabolic benefits. Semaglutide showed indirect behavioral benefits in real-world observational data. Adverse events were predominantly mild gastrointestinal symptoms.
conclusionGLP-1 RAs—particularly exenatide and semaglutide—exhibit promising neurobehavioral and metabolic effects in smoking cessation. Their dual mechanism may address key limitations of current pharmacotherapies. Larger, mechanistically enriched trials are warranted to validate efficacy and guide clinical translation for nicotine dependence and related substance use disorders.
Indexed as
Identifiers
41697556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.